We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 07, 2020

Osimertinib in EGFR+ NSCLC Patients With Brain Metastases or Leptomeningeal Disease Who Progressed on EGFR TKIs

Annals of Oncology

 

Additional Info

Annals of Oncology
A Phase II, Multicenter, Two Cohort Study of 160 mg Osimertinib in EGFR T790M-Positive Non-Small-Cell Lung Cancer Patients With Brain Metastases or Leptomeningeal Disease Who Progressed on Prior EGFR TKI Therapy
Ann. Oncol 2020 Oct 01;31(10)1397-1404, S Park, MH Lee, M Seong, ST Kim, JH Kang, BC Cho, KH Lee, EK Cho, JM Sun, SH Lee, JS Ahn, K Park, MJ Ahn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading